MammaPrint Clinical Utility UltraLow Risk



Agendia's MammaPrint® 70-gene test enables clinicians to identify women* with a genomically UltraLow Risk of recurrence so they can confidently optimize treatment plans, avoiding potential overtreatment, while ultimately helping improve quality of life.

MAMMAPRINT INDEX



Guiding **Endocrine** Decisions

ENDOCRINE DE-ESCALATION CONSIDERATIONS WITH MAMMAPRINT ULTRALOW RISK RESULTS

JAMA Oncol, 2017 Nov

EVIDENCE					
	STO-3 RCT	IKA RCT	FOCUS	MINDACT RCT	
	2-5yrs tam VS no ET	No tam 1yr tam Only 1yr tam +2yrs tam	No tam Tam	No ET 5-yr ET ET+CT	
Total number of patients (n)	652 Patients	135 Patients	418 Patients	6693 Patients	
% UltraLow Risk	15%	17%	12%	15%	
Number of UltraLow Risk patients	98	23	50	1000	
Primary Outcome for UltraLow Risk	97% BCSS at 20yrs	100% RFI at 8yrs	98% DRFI at 10yrs	99% BCSS at <u>8yrs</u> Prospective Trial	
	Esserman et al,	Opdam et al,	Noordhoek et al,	Lopes Cardozo et al,	

Breast Cancer Res Treat 2022 Jul

J Geriatr Oncol, 2022

J Clin Oncol, 2022

* 18 years or older


Guiding Chemotherapy Decisions

CHEMOTHERAPY **DE-ESCALATION** CONSIDERATIONS WITH MAMMAPRINT ULTRALOW RISK RESULTS


Identify women with breast cancer <50 yrs with MP UltraLow risk to potentially avoid harmful overtreatment with chemotherapy

EVIDENCE				
	MINDACT			
Total number of patients (n)	6,693			
% UltraLow Risk pre-menopausal	30%			
Number of UltraLow Risk patients	1000			
Primary outcome for UltraLow risk regardles of clinical risk	8-year BCSS above 99% Clin-Low: 99.7% Clin-High: 99.2% 8-year DMFI rate of 97%			

Lopes Cardozo, JCO (2022



UltraLow Risk outcomes by Menopausal Status



UltraLow Risk outcomes by Treatment

.opes Cardozo, JCO (2022)

MammaPrint UltraLow is included in the 2023 NCCN Guidelines 'Gene Expression Assays for Consideration of Adjuvant Systemic Therapy'

Visit www.nccn.org to learn more



AGENDIA° MAMMAPRINT+BLUEPRINT